ITB-MED Employee Directory
Biotechnology ResearchNew York, United States11-50 Employees
ITB-MED is a biotechnology research company focused on developing a proprietary antagonistic CD2-directed monoclonal antibody, referred to as TCD601 (siplizumab). The organization centers its efforts on exploring applications in transplantation and autoimmunity, pursuing worldwide clinical trial activity to assess potential benefits in immune modulation. Based in New York City, ITB-MED operates with a research-oriented mandate, aiming to broaden its portfolio of preclinical therapies that could extend immune-system–related treatment options. The company’s work targets clinical contexts where an immune response plays a central role, seeking to address unmet needs in organ transplantation and autoimmune conditions. A recent development noted in trade coverage mentions ITB-MED’s ongoing work toward treatment options that could influence post-transplant immunosuppression, reflecting its emphasis on expanding practical applications of its immune-modulating approach.
1-888-653-2347 
support@leadiq.com 
